Breaking News Instant updates and real-time market news.

ZLAB

Zai Lab

$32.56

0.64 (2.01%)

, DCPH

Deciphera

$36.32

-1.22 (-3.25%)

08:25
09/03/19
09/03
08:25
09/03/19
08:25

Zai Lab says Deciphera to submit NDA to FDA for ripretinib in 1Q20

The company announced upcoming milestones for ripretinib: Deciphera to present INVICTUS data at an upcoming medical conference; Deciphera to submit NDA to the U.S. FDA for fourth-line and fourth-line plus GIST by the first quarter of 2020; Discussions with the NMPA for an accelerated approval for fourth-line and fourth-line plus GIST, leveraging the INVICTUS data; Potential China CTA approval for INTRIGUE trial for second-line GIST patients and contribute Chinese patients to the global registrational study.

ZLAB

Zai Lab

$32.56

0.64 (2.01%)

DCPH

Deciphera

$36.32

-1.22 (-3.25%)

  • 03

    Sep

  • 04

    Sep

  • 20

    Sep

ZLAB Zai Lab
$32.56

0.64 (2.01%)

02/07/19
SBSH
02/07/19
UPGRADE
SBSH
Buy
Citi double upgrades MacroGenics to Buy from Sell even after 130% stock rally
Citi analyst Yigal Nochomovitz double upgraded MacroGenics (MGNX) to Buy from Sell and raised his price target for the shares to $39 from $10. The stock closed yesterday up 130%, or $14.49, to $25.60. Following yesterday's data, the analyst raised his probability of success estimate to 70% from 50% for enoblituzumab in head and neck squamous cell carcinoma and non-small cell lung cancer. Additional Phase 1 readouts in 2019 should provide further stock momentum for MacroGenics, Nochomovitz tells investors in a research note. The analyst also sees MacroGenics as positive for Zai Lab (ZLAB). The Sophia data go a long way to validate Zai's choice of partner in MacroGenics, says the analyst.
07/05/19
MACQ
07/05/19
INITIATION
MACQ
Outperform
Zai Lab initiated with an Outperform at Macquarie
07/12/19
BOFA
07/12/19
INITIATION
Target $43
BOFA
Buy
Zai Lab initiated with a Buy at BofA/Merrill
BofA Merrill Lynch analyst Yang Huang initiated Zai Lab with a Buy rating and $43 price target, citing what he views as its strong pipeline of "potential blockbusters" and its emerging in-house discovery abilities.
08/27/19
08/27/19
NO CHANGE

Zai Lab management to meet with SVB Leerink
Meetings to be held in Boston on August 26-30 hosted by SVB Leerink.
DCPH Deciphera
$36.32

-1.22 (-3.25%)

08/14/19
LEER
08/14/19
NO CHANGE
Target $29
LEER
Underperform
Deciphera price target raised to $29 from $20 at SVB Leerink
SVB Leerink analyst Andrew Berens raised his price target for Deciphera to $29 from $20 following positive top-line data from the company's Phase 3 INVICTUS trial that exceeded his expectations, in addition to favorable updates to the Phase 1 ripretinib data. The analyst reiterates an Underperform rating on the shares.
08/14/19
RHCO
08/14/19
NO CHANGE
Target $60
RHCO
Buy
Deciphera price target raised to $60 from $45 at SunTrust
SunTrust analyst Peter Lawson raised his price target on Deciphera to $60 and kept his Buy rating after its positive topline data presented for the Phase 3 trial of ripretinib in gastrointestinal stromal tumors, or GIST. The analyst says the results give him more confidence moving into the second line GIST trial and may help enrollment in the ongoing Phase 3 study. Lawson is also increasing his probability of success for the program to 90% from 80% as well as his assumed penetration to 60% from 40% in 4L+ GIST.
08/20/19
PIPR
08/20/19
NO CHANGE
Target $55
PIPR
Overweight
Deciphera still offers 'significant upside', says Piper Jaffray
Piper Jaffray analyst Christopher Raymond kept his Overweight rating and $55 price target on Deciphera (DCPH), anticipating several catalysts over the next few quarters to play out. The analyst cites continued upside from ripretinib's profile in earlier lines of GIST to continue to emerge and also believes the stock can benefit from an increasingly flattering comp from its competitor Blueprint Medicines' (BPMC) avapritinib, particularly as the toxicity of that agent becomes more apparent.
08/29/19
PIPR
08/29/19
INITIATION
Target $85
PIPR
Neutral
Blueprint Medicines initiated with a Neutral at Piper Jaffray
Piper Jaffray analyst Christopher Raymond started Blueprint Medicines (BPMC) with a Neutral rating and $85 price target. The analyst, while impressed with the company's "well demonstrated developmental track record and platform capability," sees a full valuation at current share levels. Further, the competitive disadvantage for Blueprint's lead asset avapritinib relative to Deciphera's (DCPH) ripretinib is not completely understood, Raymond tells investors in a research note.

TODAY'S FREE FLY STORIES

01:50
09/17/19
09/17
01:50
09/17/19
01:50
General news
FX Update: The Australian dollar ebbed to an 11-day low »

FX Update: The Australian…

01:35
09/17/19
09/17
01:35
09/17/19
01:35
General news
FX Action: »

FX Action: The Dollar…

01:25
09/17/19
09/17
01:25
09/17/19
01:25
General news
FOMC outlook: »

FOMC outlook: the Fed…

01:25
09/17/19
09/17
01:25
09/17/19
01:25
General news
Asian Market Wrap: »

Asian Market Wrap:…

XLRN

Acceleron

$44.67

0.75 (1.71%)

22:05
09/16/19
09/16
22:05
09/16/19
22:05
Recommendations
Acceleron analyst commentary at Piper Jaffray »

Acceleron's ACE-083…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 17

    Oct

  • 04

    Dec

  • 04

    Apr

PNRL

Paringa Resources

$2.28

-0.06 (-2.56%)

20:18
09/16/19
09/16
20:18
09/16/19
20:18
Hot Stocks
Paringa Resources names Jim Middleton as Executive Advisor »

Paringa Resources is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RBNC

Reliant Bancorp

$24.70

0.16 (0.65%)

20:17
09/16/19
09/16
20:17
09/16/19
20:17
Hot Stocks
Reliant Bancorp to buy Tennessee Community Bank Holdings for $37.2M »

Reliant Bancorp announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

ORCL

Oracle

$53.12

-0.64 (-1.19%)

, INTC

Intel

$52.21

-0.32 (-0.61%)

19:12
09/16/19
09/16
19:12
09/16/19
19:12
Hot Stocks
Intel, Oracle collaborate on Optane DC Persistent Memory »

Intel (INTC) and Oracle…

ORCL

Oracle

$53.12

-0.64 (-1.19%)

INTC

Intel

$52.21

-0.32 (-0.61%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

ORCL

Oracle

$53.12

-0.64 (-1.19%)

, VMW

VMware

$155.87

4.81 (3.18%)

19:08
09/16/19
09/16
19:08
09/16/19
19:08
Hot Stocks
VMware, Oracle expand partnership on hybrid cloud »

Oracle (ORCL) and VMware…

ORCL

Oracle

$53.12

-0.64 (-1.19%)

VMW

VMware

$155.87

4.81 (3.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Oct

ACRS

Aclaris Therapeutics

$1.09

0.06 (5.83%)

, BBCP

Concrete Pumping

$4.40

0.265 (6.41%)

19:05
09/16/19
09/16
19:05
09/16/19
19:05
Hot Stocks
Fly Intel: After Hours Movers »

HIGHER: Aclaris…

ACRS

Aclaris Therapeutics

$1.09

0.06 (5.83%)

BBCP

Concrete Pumping

$4.40

0.265 (6.41%)

GLW

Corning

$30.04

-0.12 (-0.40%)

XLRN

Acceleron

$44.67

0.75 (1.71%)

SHOP

Shopify

$337.93

-0.77 (-0.23%)

KHC

Kraft Heinz

$29.62

0.37 (1.27%)

PSTV

Plus Therapeutics

$9.51

-0.05 (-0.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Sep

  • 18

    Sep

  • 01

    Oct

  • 17

    Oct

  • 17

    Oct

  • 04

    Dec

  • 04

    Apr

  • 17

    Sep

KHC

Kraft Heinz

$29.62

0.37 (1.27%)

19:03
09/16/19
09/16
19:03
09/16/19
19:03
Hot Stocks
3G Capital sells 25.1M shares of Kraft Heinz »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

KHC

Kraft Heinz

$29.62

0.37 (1.27%)

18:53
09/16/19
09/16
18:53
09/16/19
18:53
Hot Stocks
Kraft Heinz's Lemann acquires nearly 3.5M common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

HMSY

HMS Holdings

$37.14

0.24 (0.65%)

18:43
09/16/19
09/16
18:43
09/16/19
18:43
Hot Stocks
HMS Holdings acquires VitreosHealth for approximately $36.5M »

HMS Holdings announced it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

18:25
09/16/19
09/16
18:25
09/16/19
18:25
General news
U.S. industrial production preview: »

U.S. industrial…

18:25
09/16/19
09/16
18:25
09/16/19
18:25
General news
Treasury Market Summary »

Treasury Market Summary:…

ICAD

iCAD

$6.89

-0.01 (-0.14%)

18:25
09/16/19
09/16
18:25
09/16/19
18:25
Conference/Events
iCAD to hold an investor reception »

Management hosts "An…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Sep

  • 12

    Nov

GLW

Corning

$30.04

-0.12 (-0.40%)

18:18
09/16/19
09/16
18:18
09/16/19
18:18
Hot Stocks
Corning down 5.5% or $1.64 at $28.40 per share after cutting volume outlook »

As part of the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WE

We Company

$0.00

(0.00%)

18:17
09/16/19
09/16
18:17
09/16/19
18:17
Periodicals
We Company IPO delayed until October at earliest, WSJ reports »

The We Company's IPO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLW

Corning

$30.04

-0.12 (-0.40%)

18:16
09/16/19
09/16
18:16
09/16/19
18:16
Hot Stocks
Corning cuts Q3 volume guidance for Display and Optical Communications units »

Corning is providing the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WE

We Company

$0.00

(0.00%)

18:05
09/16/19
09/16
18:05
09/16/19
18:05
Periodicals
Breaking Periodicals news story on We Company »

We Company IPO delayed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GM

General Motors

$37.21

-1.62 (-4.17%)

18:02
09/16/19
09/16
18:02
09/16/19
18:02
Periodicals
Auto workers strike could cost GM $100M daily, WSJ says »

General Motors could lose…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HLNE

Hamilton Lane

$59.95

-0.51 (-0.84%)

17:57
09/16/19
09/16
17:57
09/16/19
17:57
Hot Stocks
Hamilton Lane vice chairman sells 150K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

17:52
09/16/19
09/16
17:52
09/16/19
17:52
Conference/Events
SVB Leerink biotech analysts to hold analyst/industry conference call »

Biotech Analysts discuss…

HLNE

Hamilton Lane

$59.95

-0.51 (-0.84%)

17:52
09/16/19
09/16
17:52
09/16/19
17:52
Hot Stocks
Hamilton Lane chairman sells 78.5K shares of common »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

GD

General Dynamics

$190.91

0.98 (0.52%)

, BAH

Booz Allen

$70.35

0.85 (1.22%)

17:44
09/16/19
09/16
17:44
09/16/19
17:44
Hot Stocks
General Dynamics, Booz Allen and Parsons awarded $427M max Air Force contract »

General Dynamics (GD),…

GD

General Dynamics

$190.91

0.98 (0.52%)

BAH

Booz Allen

$70.35

0.85 (1.22%)

PSN

Parsons

$37.25

0.35 (0.95%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.